Nemonapride
From Wikipedia, the free encyclopedia
![]() |
|
Clinical data | |
---|---|
Trade names | Emilace (JP) |
AHFS/Drugs.com | International Drug Names |
Routes of administration |
Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
ECHA InfoCard | 100.215.765 |
Chemical and physical data | |
Formula | C21H26ClN3O2 |
Molar mass | 387.90 g/mol |
3D model (Jmol) | |
|
|
|
|
(verify) |
Nemonapride (エミレース, Emilace (JP)) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in 1991. Nemonapride acts as a D2 and D3 receptor antagonist, and is also a potent 5-HT1A receptor agonist. It has affinity for sigma receptors.
See also[edit]
References[edit]
This article does not cite any sources. (November 2009) (Learn how and when to remove this template message) |
![]() |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |